Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 11/20 | 0.46 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17504780 | 0.86 | FOLH1 (0.46) | FOLH1NAALAD2CA1CA2GRM3 | |
| SCHEMBL17533535 | 0.86 | FOLH1 (0.65) | FOLH1NAALAD2GRM3 | |
| SCHEMBL27210236 | 0.77 | CA2 (0.62) | CA1CA2 | |
| SCHEMBL20464696 | 0.76 | SLC1A1 (0.47) | CA1CA2 | |
| SCHEMBL17504784 | 0.73 | FOLH1 (0.50) | FOLH1 | |
| SCHEMBL13955062 | 0.72 | SLC1A1 (0.41) | FOLH1NAALAD2CA1CA2GRM3 | |
| SCHEMBL19225283 | 0.72 | FOLH1 (0.47) | FOLH1NAALAD2GRM3 | |
| SCHEMBL2000276 | 0.71 | FOLH1 (0.53) | FOLH1NAALAD2CA1CA2 | |
| SCHEMBL19220619 | 0.71 | FOLH1 (0.34) | FOLH1NAALAD2 | |
| SCHEMBL27874318 | 0.71 | FOLH1 (0.53) | FOLH1NAALAD2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988407-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170226141-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226141-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | FOLH1, KLK3, DNPEP | FOLH1 1/4885NAALAD2 111/4885CA1 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.